Last edition
News about "AstraZeneca"
The first patient has been dosed in the global Phase 3 TROPION-Urothelial04 trial, advancing evaluation of Datroway-based therapies for high-risk muscle-invasive urothelial cancer.
AstraZeneca | 27/08/2026 | By News Bureau
SOPHiA GENETICS and AstraZeneca Partner to Develop Two Companion Diagnostics for Precision Oncology
SOPHiA GENETICS and AstraZeneca have launched a multi-year collaboration to develop two companion diagnostics for solid tumours and blood cancers, supporting broader access to precision oncology therapies.
AstraZeneca | 18/08/2026 | By News Bureau
Enhertu Plus Pertuzumab Approved in China for First-Line HER2-Positive Metastatic Breast Cancer
Enhertu plus pertuzumab has been approved in China as first-line treatment for HER2-positive metastatic breast cancer, based on positive phase 3 results.
AstraZeneca | 13/08/2026 | By News Bureau | 101
Lupin Secures US Approval for Sodium Zirconium Cyclosilicate Oral Suspension
Lupin has received US Food and Drug Administration (FDA) approval for Sodium Zirconium Cyclosilicate Oral Suspension, 5 g and 10 g, bioequivalent to AstraZeneca’s Lokelma.
AstraZeneca | 11/08/2026 | By News Bureau
Pathos AI, AstraZeneca Partner to Advance AI-Driven Breast Cancer Therapy into Clinical Development
Pathos AI and AstraZeneca have entered a strategic collaboration to advance AZD4241, an investigational therapy for ER+/HER2- breast cancer, using artificial intelligence to enhance clinical development and precision oncology.
AstraZeneca | 05/08/2026 | By News Bureau | 104
EU Approves Datroway for First-Line Metastatic TNBC
The European Union (EU) has approved AstraZeneca and Daiichi Sankyo's Datroway for first-line metastatic Triple Negative Breast Cancer (TNBC), backed by positive phase 3 survival and PFS results.
AstraZeneca | 01/08/2026 | By News Bureau | 115
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
AstraZeneca | 28/07/2026 | By News Bureau
CHMP Recommends AstraZeneca's Trixeo for EU Approval in Asthma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended EU approval of AstraZeneca's Trixeo for asthma maintenance, backed by positive phase 3 KALOS and LOGOS trial results.
AstraZeneca | 25/07/2026 | By News Bureau | 139
EU Approves AstraZeneca's Etcamah Combination for ESR1-Mutated Advanced Breast Cancer
The European Commission has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors for ESR1-mutated ER-positive, HER2-negative advanced breast cancer, following Phase 3 data demonstrating a 56% reduction in the risk of disease progression or death.
AstraZeneca | 24/07/2026 | By News Bureau
AstraZeneca Enters into Global License Agreement with with Dizal Pharmaceutical for Zegfrovy
AstraZeneca has entered a global licensing agreement with Dizal Pharmaceutical for Zegfrovy, expanding its EGFR-targeted lung cancer portfolio.
AstraZeneca | 15/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy